Genmab — December 2018

Solsen

Yes JW have said as Sukkeralf reffering.

Sukkeralf

Jan also mentioned that Roche/Genentech had 3 CD3/CD20 BsAb - two in the clinic and one preclinical. So guess not interested begore Genmab present outstanding data

Solsen

I dont think the bite technology is competitive

Sukkeralf

Too old - was it regeneron that also had a BCMA-CD3 BsAb at ASH ?

E_L

i guess it is too early to expect any data from Genmab´s cd3cd20 presentation tonight?

Sukkeralf

Way too early - maybe ASH next year

Solsen

If you work with three bsabs at Genentech it certainly dont look like they have found the needle in the haystack

bibob

Maybe Genmab have the needle.

Sukkeralf

Jan said Its because Its so hard to predict what you exactly need - three is better than one

Sukkeralf

But nice data for BsAbs will give more value to Genmabs preclinical and early pipeline as it based on this

Solsen

Discontinuation was relative high in Regenerons trial. The silencing of the CD3 arm could be the right way

Bulder

Just a detail: It's not the cd3-arm that is silenced. It's the Fc-part.

Solsen

Correct

Solsen

The data presented at ASH included a total of 68 patients with R/R B-NHL who were treated with REGN1979. These patients had received a median of three prior therapies, including an anti-CD20 therapy. As of September 2018, 14 patients had completed treatment, 13 patients remained on treatment and 41 had discontinued treatment. The most common reason for treatment discontinuation was progressive disease (27 patients).

Solsen

2/3 of pts discontinued !

E_L

https://twitter.com/DrOmarNadeem/status/1068937605721448448

E_L

on Griffin https://twitter.com/akeithstewart/status/1068961191349764096

peter12

Hvordan kan de skrive 100% ORR når 66% stopper ?

E_L

JNJ news release https://www.prnewswire.com/news-releases/darzalex-daratumumab-combination-regimens-show-positive-results-for-newly-diagnosed-and-relapsed-patients-with-multiple-myeloma-300758631.html

Solsen

Griffin are outstanding